Press Releases
Hop-on's Digitalage Targets Enterprise Licensing for AI-Assisted Moderation Technology
Former Nokia licensing executive Robert T. Braun joins industry leaders at IAM Live as Digitalage prepares its first enterprise-licensing candidate and creator-platform launch TEMECULA, CA / ACCESS Newswire / October 23, 2026 / Hop-on, Inc. (OTCID:HPNN) today identified AI-assisted text moderation as the first technology its wholly owned subsidiary, Digitalage, Inc., is preparing for enterprise evaluation and potential licensing...
Century Aluminum Sets Date for Third Quarter 2026 Earnings Announcement
CHICAGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) will report third quarter 2026 earnings on Thursday, November 5, 2026, after market close. The news release will be issued through GlobeNewswire.
Key Tronic Corporation Announces First Quarter Reporting Date
SPOKANE VALLEY, Wash., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Key Tronic Corporation (Nasdaq: KTCC), announced today that it plans to report its results for the first quarter of fiscal 2027 after market close on November 3rd, 2026.
Yiren Digital Ltd. Investor News: If You Have Suffered Losses in Yiren Digital Ltd.
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Yiren Digital Ltd. (NYSE: YRD) resulting from allegations that Yiren may have issued materially misleading business information to the investing public...
EON Resources Inc. Announces 2nd Quarter 2026 Earnings Call to be held Wednesday, October 28, 2026
Management Will Be Discussing Its Financial Results, Accomplishments and Plans for the Remainder of 2026 HOUSTON, TX / ACCESS Newswire / October 23, 2026 / EON Resources Inc. (NYSE American:EONR) ("EON" or the "Company") is an independent upstream energy company with 20,000 leasehold acres comprised of two fields and 700 total producing and injection wells which it operates with 1,000 barrels a day of oil produced in the Permian Basin in southeast New Mexico. The Company filed its 10-Q for Q2 2026 yesterday, Thursday, October 22, 2026...
Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended September 30, 2026
NEW YORK, Oct. 23, 2026 /PRNewswire/ -- Hyperliquid Strategies Inc (NASDAQ: PURR) ("HSI" or the "Company"), the premier digital asset treasury platform focused on the Hyperliquid ecosystem, today announced that it will host a live webcast on Thursday, November 5, 2026, at 5:15 p.m. Eastern Time to present its financial and operational results for the quarter ended September 30, 2026...
Wolters Kluwer launches agentic tax preparation in CCH Axcess, the agentic platform for tax and accounting
MINNEAPOLIS--(BUSINESS WIRE)--Wolters Kluwer Tax & Accounting today announced the launch of agentic tax return preparation in CCH Axcess™ Tax, further advancing CCH Axcess as the agentic platform for tax and accounting. Built into the cloud-native platform where firms already manage their tax work, agentic tax preparation helps firms reduce repetitive preparation work, increase capacity, and give tax professionals a stronger starting point for review. For individual Form 1040 returns, CCH A...
What Should Better Home & Finance Holding Company Investors Know After 28.5% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Better Home & Finance Holding Company made misleading statements to investors from March 13, 2026 to May 7, 2026; lead plaintiff motions are due November 20, 2026 LOS ANGELES, Oct. 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Better Home & Finance Holding Company ("Better Home & Finance" or the "Company") (NASDAQ: BETR) on behalf of investors who acquired the Company's securities from March 13, 2026 to May 7, 2026...
What Should Baidu, Inc. Investors Know After 12.73% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Baidu, Inc. made misleading statements to investors from November 18, 2025 to August 17, 2026; lead plaintiff motions are due November 13, 2026 LOS ANGELES, Oct. 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Baidu, Inc. ("Baidu" or the "Company") (NASDAQ: BIDU) on behalf of investors who acquired the Company's securities from November 18, 2025 to August 17, 2026...
What Should Bank Of America Corporation Investors Know After 4.76% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Bank Of America Corporation made misleading statements to investors from August 1, 2025 to October 13, 2026; lead plaintiff motions are due December 15, 2026 LOS ANGELES, Oct. 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Bank Of America Corporation ("Bank of America" or the "Company") (NYSE: BAC) on behalf of investors who acquired the Company's securities from August 1, 2025 to October 13, 2026...
What Does Gildan Activewear Inc.'s 18.8% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Gildan Activewear Inc. failed to disclose key facts to investors from February 19, 2025 through June 15, 2026; lead plaintiff deadline is December 14, 2026 BENSALEM TOWNSHIP, Pa., Oct. 23, 2026 /PRNewswire/ -- The Law Offices of Howard G.
Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers.
What Does Netcapital Inc.'s 28.62% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Netcapital Inc. failed to disclose key facts to investors from December 15, 2021 through September 3, 2026; lead plaintiff deadline is December 7, 2026 BENSALEM TOWNSHIP, Pa., Oct. 23, 2026 /PRNewswire/ -- The Law Offices of Howard G.
PennyMac Mortgage Investment Trust Reschedules Third Quarter 2026 Earnings Call to 6:30 PM ET on Thursday, October 29
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Mortgage Investment Trust (NYSE: PMT) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. The conference call and live audio webcast is being rescheduled to 6:30 pm. Eastern Time from the originally scheduled 6:00 p.m. Eastern Time. The release, webcast, and accompanying materials will be available online at pmt.pennymac.com. A replay of the webcas...
Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week
The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience LUND, Sweden, October 23, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that data from the European Post-Authorization Efficacy and Safety (PAES) study of Idefirix (imlifidase) were presented during the High-Impact Clinical Trials oral session at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. The abstract "FR-OR103 Post-Authorization Efficacy and Safety (PAES): An Open-Label Post-Authorization Trial of 50 Imlifidase Crossmatch-Positive Deceased-Donor Kidney Transplants in Europe" was selected as a Late-Breaking Abstract at the congress...
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a...
PennyMac Financial Services, Inc. Reschedules Third Quarter 2026 Earnings Call to 5:30 PM ET on Thursday, October 29
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Financial Services, Inc. (NYSE: PFSI) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. The conference call and live audio webcast is being rescheduled to 5:30 pm. Eastern Time from the originally scheduled 5:00 p.m. Eastern Time. The release, webcast, and accompanying materials will be available online at pfsi.pennymac.com. A replay of the webca...
What Does Alphabet Inc.'s 7.13% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Alphabet Inc. failed to disclose key facts to investors from May 19, 2026 through July 16, 2026; lead plaintiff deadline is December 1, 2026 BENSALEM TOWNSHIP, Pa., Oct. 23, 2026 /PRNewswire/ -- The Law Offices of Howard G.
NextGen Healthcare Appoints Anthony Palladino as Chief Financial Officer
DETROIT--(BUSINESS WIRE)-- #NextGenHealthcare--NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, today announced Anthony Palladino as Chief Financial Officer. Palladino joins NextGen Healthcare from Thoma Bravo, where he served as an operating partner, working alongside portfolio company leadership teams to strengthen financial operations, improve operating efficiency and accelerate profitable growth across the firm's software portfolio. Prior to Thoma Bravo, Palladi...
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today late-breaking oral presentation data from the ongoing Phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P
Macy's, Inc. Board of Directors Declares Quarterly Dividend
NEW YORK--(BUSINESS WIRE)--Macy's, Inc. Board of Directors Declares Quarterly Dividend.
What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Anavex Life Sciences Corp. failed to disclose key facts to investors from November 26, 2025 through August 28, 2026; lead plaintiff deadline is November 30, 2026 BENSALEM TOWNSHIP, Pa., Oct. 23, 2026 /PRNewswire/ -- The Law Offices of Howard G.
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P
The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme
HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors' medications. In many cases, these presc...
Lyntris Schedules Third Quarter Fiscal Year 2026 Earnings Release, Conference Call, and Webcast
WASHINGTON--(BUSINESS WIRE)--Lyntris Inc. (NYSE: LYNX), a defense technology company delivering integrated sensing, communications, and mission systems, today announced it will issue financial results for the third quarter fiscal year 2026 on Wednesday, November 4, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 PM Eastern Time. Hosting the call and webcast will be Brian Morrison, CEO; Matt Alty, President and Vice Chair; Tim Paulin, CFO; and N...
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue
DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) cleared several key resistance levels, on strong trading volume, delivering a potentially important technical signal for a stock that recently tested lows near $2.50. The breakout marks a significant development from its recent chart snapshots...
Telesat schedules third quarter 2026 earnings conference call for October 29, 2026
OTTAWA, Ontario, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Telesat (Nasdaq and TSX: TSAT), one of the world's largest and most innovative satellite operators, has scheduled a conference call for Thursday, October 29, 2026, at 10:30 a.m. EDT to discuss its financial results on the three- and nine-month periods ended September 30, 2026. The call will be hosted by Daniel S. Goldberg, President and Chief Executive Officer, and Donald Tremblay, Chief Financial Officer, of Telesat...
Popular, Inc. Declares a Cash Dividend of $0.90 per Common Share
SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Popular, Inc. (NASDAQ: BPOP) announced today that its Board of Directors has approved a quarterly cash dividend of $0.90 per share on its outstanding common stock. The dividend will be payable on January 4, 2027 to shareholders of record at the close of business on November 13, 2026. About Popular, Inc. Popular, Inc. (NASDAQ: BPOP) is the leading financial institution by both assets and deposits in Puerto Rico and ranks among the top 50 U.S. bank holding...
Sigma Lithium Extends 4-Year US$100 Million Senior Secured Debt to June 2027; 7,090t Produced Since Restart
HIGHLIGHTS Sigma Lithium extends the maturity of its 4-year US$100M senior secured debt with Synergy Capital by six months, from December 2026 to June 2027. The interest rate on the senior secured facility remained unchanged at SOFR + 6.95% p.a.
Cirrus Breaks Ground on New Engine Run-Up Center
DULUTH, Minn.--(BUSINESS WIRE)-- #Cirrus--Cirrus (Cirrus Aircraft Ltd.), the global leader in Personal Aviation™, broke ground on the 15,000-square-foot Engine Run-Up Center, designed to safely and efficiently test SR Series, Vision Jet, and TRAC10 engine system functionality, performance, and fuel calibration as part of the aircraft certification process. Cirrus will invest over $8 million in the facility, which will provide a centralized, enclosed, well-equipped, climate-controlled building year-round...
Nasdaq Confirms Yimutian's Return to Compliance
BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that it has received a letter dated October 20, 2026 from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum stockholders' equity requirement of US$2.5 million under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). Nasdaq also confirmed that the Company has met all requirements set forth in the Nasdaq Hearings Panel's decision dated July 8, 2026...
Fresh Energy, Expanding Possibilities
Lithium sourcing ideas and charging innovation shape a multi-track outlook for OTC: ELEK. WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2026 / ELEKTROS Inc. (OTC PINK:ELEK) (the "Company") today outlined a renewed perspective on its emerging lithium and electric-vehicle infrastructure interests, highlighting opportunities under consideration while emphasizing the diligence required to move from ideas to measurable progress...
Verisk Comments on Delaware Supreme Court Order Regarding AccuLynx
JERSEY CITY, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, today issued the following statement in response to the Delaware Supreme Court order regarding the AccuLynx transaction:
Hubbell Incorporated Declares a 7% Dividend Increase
Shelton, CT, Oct. 23, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Hubbell Incorporated (NYSE:HUBB) today declared a 7% increase in its common stock dividend rate. The new annual payment of $6.08 per share, or $1.52 per quarter, compares to the former rate of $5.68 per share, or $1.42 per quarter. The dividend will be paid on December 15, 2026 to shareholders of record on November 30, 2026...
Green Plains to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026
OMAHA, Neb.--(BUSINESS WIRE)--Green Plains Inc. (NASDAQ:GPRE) will release third quarter 2026 financial results after the market closes on November 5, 2026, and then host a conference call beginning at 4:30 p.m. Eastern time (3:30 p.m. Central time) to discuss the results and outlook. Domestic and international participants can access the conference call by dialing 833.461.5787 and 585.542.9983, respectively, and referencing conference ID 198456298. Participants are advised to call at least 10...
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Company Announcement COPENHAGEN, Denmark; October 23, 2026 Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S ) compared to investigator's choice chemotherapy Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC) Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S ), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC) , in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab. The trial met its primary endpoint of progression-free survival (PFS), with Rina-S demonstrating a statistically significant and clinically meaningful improvement compared with investigator's choice chemotherapy in the intent-to-treat (ITT) and in the primary analysis set (PAS) populations...
Elektros Opens a New Chapter: Exploring American Lithium Potential and the Road Ahead
Company outlines a measured path across domestic lithium evaluation, international logistics and patented EV charging innovation A Fresh Perspective on Opportunity WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2026 / ELEKTROS Inc. (OTC PINK:ELEK) (the "Company") is entering a new day with a renewed focus on identifying opportunities that could shape its long-term direction. From preliminary lithium prospects in northern New York to possible connections between Sierra Leone lithium logistics and U.S. refining, ELEKTROS is evaluating where disciplined research, capable partners and practical execution may intersect...
A New Horizon for American Lithium
WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2026 / ELEKTROS Inc. (OTC PINK:ELEK) (the "Company") today outlined a renewed perspective on its emerging lithium and electric-vehicle infrastructure interests, highlighting opportunities under consideration while emphasizing the diligence required to move from ideas to measurable progress. A Fresh Look at Domestic Opportunity A new chapter of evaluation is taking shape as ELEKTROS Inc. considers whether lithium-bearing properties in northern New York, near the Canadian border, may warrant further technical and commercial study...
Worthington Steel Confirms Its Kloeckner Strategy Following Shareholder Vote
COLUMBUS, Ohio--(BUSINESS WIRE)--Worthington Steel Confirms Its Kloeckner Strategy Following Shareholder Vote.
S&P Global Ratings Upgrades CFC to ‘A'; Outlook Stable
DULLES, Va., Oct. 23, 2026 (GLOBE NEWSWIRE) -- National Rural Utilities Cooperative Finance Corporation (CFC) has announced that S&P Global Ratings (S&P) has upgraded its long-term issuer credit rating to “A” from “A-” with a Stable Outlook.
Gannon University MakerSpace Joins NFI Empire's Project REBORN #001, Using 3D Printing to Create Custom Trim and Badging
Some Parts Can't Be Bought. They Have to Be Reimagined: Gannon University MakerSpace Helps Bring Project REBORN #001 to Life NORTH EAST, PA / ACCESS Newswire / October 23, 2026 / NFI Empire, a fully owned subsidiary of Newport Gold, Inc. (OTCID:NWPG), today announced that Gannon University's MakerSpace has joined Project Reborn-001 as a technology and fabrication partner...
Club Offers for Travel Enthusiasts in Germany
BERLIN, Oct. 23, 2026 /PRNewswire/ -- Travelzoo (NASDAQ: TZOO), the club for travel enthusiasts, announces five of many new Club Offers for Club Members in Germany. Rigorously vetted and negotiated for us travel enthusiasts: €79 PP—3 DAYS IN DRESDEN'S OLD TOWNBreakfast included.
Kaplan Fox Reminds Innventure, Inc. (NASDAQ: INV) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 27, 2026
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Innventure, Inc. (“Innventure” or the “Company”) (NASDAQ: INV) on behalf of investors that purchased or otherwise acquired Innventure securities between November 17, 2025 and August 13, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Innventure and have suffered losses, you may CLICK HERE to contact us...
Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Act Ahead of the Lead Plaintiff Deadline on November 3, 2026
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us...
Kaplan Fox Urges AppLovin Corporation (NASDAQ: APP) Investors Seeking Recovery to Contact the Firm Before November 16, 2026
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AppLovin Corporation (“AppLovin” or the “Company”) (NASDAQ: APP) on behalf of investors that purchased or otherwise acquired AppLovin securities between February 12, 2026 and August 5, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in AppLovin and have suffered losses, you may CLICK HERE to contact us...
Drone Nerds Introduces ABZ Innovation C30 High-Pressure Cleaning Drone to Enterprise Portfolio
ABZ Innovation's new industrial cleaning drone expands Drone Nerds' offerings for infrastructure maintenance and facility cleaning applications FORT LAUDERDALE, Fla., Oct. 23, 2026 /PRNewswire/ -- XTI Aerospace, Inc. (Nasdaq: XTIA) ("XTI Aerospace," "XTI" or the "Company"), an aerospace and advanced technology platform and parent company of Drone Nerds, LLC ("Drone Nerds"), a drone solutions platform serving commercial, enterprise and government customers, today announced the addition of the new ABZ Innovation C30 high-pressure cleaning drone to Drone Nerds' enterprise solutions portfolio...
FS Bancorp, Inc. Announces the Appointment of Matthew D. Mullet as a Director of FS Bancorp, Inc.
MOUNTLAKE TERRACE, Wash., Oct. 23, 2026 (GLOBE NEWSWIRE) -- FS Bancorp, Inc. (NASDAQ: FSBW) (the “Company”), the holding company for 1st Security Bank of Washington (the “Bank”), today announced that Matthew D. Mullet had been appointed to serve on the Boards of Directors of both the Company and the Bank...
YouCam Integrates Newly Released Kling 4.0 API to Turn Photos into 30-Second Stories with Dialogue and Sound
NEW YORK--(BUSINESS WIRE)--Perfect Corp. (NYSE: PERF), a global leader in augmented reality (AR) and artificial intelligence (AI) beauty and fashion tech, today announced that YouCam is one of the first platforms to integrate the newly released Kling 4.0 API. The newest AI video model from Kuaishou Technology's Kling AI is now live across the YouCam lineup on mobile and web. Built for longer storytelling, Kling 4.0 lets users set up to 10 keyframes instead of only a first and last frame, then g...
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and were presented in a late-breaking oral sess...
Dashen Bank and ShebaMiles Launch Platinum Co-Branded Mastercard Debit Card to Unlock Premium Travel Benefits for Customers in Ethiopia
ADDIS ABABA, Ethiopia--(BUSINESS WIRE)--Dashen Bank and ShebaMiles Launch Platinum co-branded Mastercard Debit card to unlock premium travel benefits for customers in Ethiopia.
Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
SEATTLE, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced new interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These data are being presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026 in Madrid, Spain...
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients.
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies
CTS Corporation Announces Completion of the Acquisition of Millar Holdings
LISLE, Ill., Oct. 23, 2026 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE: CTS) today announced that it has completed the acquisition of Millar Holdings, Inc. (“Millar”) for $50 million, net of cash acquired and debt assumed, with additional contingent consideration payable subject to the achievement of specified financial performance targets...
Nitches, Inc. (OTC: NICH) Takes NutraVeri to Both Sides of the $200 Billion Supplement Market: Free Checks for Consumers, Readiness Intelligence for Brands
Year-end shareholder update: seven product surfaces live, a professional offer ladder to $25,000, a partner network activated, and NutraVeri Stack Check, built on public NIH records, clears its first accuracy gate with zero wrong picks across 200 searches MIAMI, FL / ACCESS Newswire / October 23, 2026 / Nitches, Inc. (OTC:NICH) today issued its year-end update on NutraVeri, the company's supplement product-readiness platform. In the second half of 2026, NutraVeri rebuilt and deployed its brand-facing platform, published a professional offer ladder from a free grade to a $25,000 manufacturer intake, activated a partner distribution network, and completed the first accuracy test of a consumer product that opens the platform to the largest audience in the category: the people who buy the bottle...
Hercules Metals Announces Upsize of "Bought Deal" Private Placement of Common Shares to $45 Million
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA (tislelizumab) plus ZIIHERA (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GE...
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the risk of death by 24% versus trastuzumab plus chemotherapy For U.S. media and investors only DUBLIN, Oct. 23, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without Tevimbra (tislelizumab-jsgr), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results from the second interim, and final formal, analysis were presented as a late-breaking rapid oral presentation (LBA79) at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain...
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Reinforces Ongoing TILVANCE-301 Phase 3 Trial PHILADELPHIA and MADRID, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that one-time lifileucel combined with pembrolizumab demonstrated a 62.5% ORR and a 29.2% CR rate, with median OS not reached at 50.9 months of median study follow-up in the final Phase 2 analysis in frontline advanced melanoma. The Phase 2 results were presented on October 23, 2026 in a Proffered Paper oral session at the ESMO Congress 2026 in Madrid, Spain...
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today presented results from an interim analysis of the DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain...
Travelzoo Q3 2026 Earnings Conference Call on October 27 at 11:00 AM ET
NEW YORK, Oct. 23, 2026 /PRNewswire/ -- Travelzoo (NASDAQ: TZOO): WHAT: Travelzoo, the club for travel enthusiasts, will host a conference call to discuss the Company's financial results for the third quarter ended September 30, 2026. Travelzoo will issue a press release reporting its results before the market opens on October 27, 2026...
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project
NEW YORK--(BUSINESS WIRE)-- #HydrometTechnology--Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company's Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment...
MINT Income Fund Distributions
TORONTO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MINT Income Fund (TSX: MID.UN) (the “Fund”) is pleased to announce that distributions for the fourth quarter of 2026 will be payable to unitholders of MINT Income Fund as follows:
The 18th Skechers Pier to Pier Friendship Walk Raises $3.3 Million for Kids
LOS ANGELES--(BUSINESS WIRE)--The 18th Skechers Pier to Pier Friendship Walk Raises $3.3 Million for Kids.
KOIL Energy Wins Significant Service Contract
HOUSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- KOIL Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, today announced the award of a significant project for Subsea Cable Management Services.
Polaris Expands Call of Duty® Collaboration as Polaris DAGOR Joins Modern Warfare® 4
Longstanding collaboration continues to bridge real-world Polaris performance with one of gaming's most iconic franchises MINNEAPOLIS, Oct. 23, 2026 /PRNewswire/ -- Polaris Inc. (NYSE: PII), the global leader in powersports, today announced the Polaris DAGOR is joining Call of Duty : Modern Warfare 4 as a playable in-game vehicle. Building on Polaris' growing presence within one of the world's most recognizable gaming franchises, the integration marks the latest milestone in the company's ongoing collaboration with Call of Duty , bringing Polaris' performance and capability to millions of players worldwide...
North Dallas Bank & Trust Co. Announces Third Quarter Earnings
DALLAS, Oct. 23, 2026 (GLOBE NEWSWIRE) -- NDBT (North Dallas Bank & Trust Co.), an independent community bank established in 1961, today announced net earnings for three months of $2,599,934 or $1.01 per share, and net earnings for nine months of $7,120,282 or $2.77 per share, for the periods ending September 30, 2026...
xETFs Launches First U.S. Listed ETF Focused on Capturing Exposure to Companies in the Samsung Group
Much more than smartphones and memory chips, the Samsung Group also has a sprawling network of companies in financials, consumer & services, life sciences and more. The xETFs Samsung Group ETF (SMNG) offers investors a single-ticker solution to accessing the Samsung Group story.
Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award
BREAKTHROUGH INNOVATION BRINGS AFFORDABLE LUXURY & COMFORT TO MAINSTREAM VEHICLES SHANGHAI, CHINA / ACCESS Newswire / October 23, 2026 / Leggett Dynamics today announced that its Mid-Class Massage System (MCM) received Gasgoo's Best Technical Practice Award during a ceremony held at the 14th annual Automotive & Environment Innovation Forum in Shanghai. The Gasgoo Best Technical Practice Award honors automotive technologies that have proven innovation, production readiness and measurable customer value in real-world vehicle applications...
Eddie Bauer Adventure Club Expands to Texas Hill Country with First Outpost
ORLANDO, Fla.--(BUSINESS WIRE)--Travel + Leisure Co. (NYSE: TNL), a leading leisure travel company, today announced its purchase of The Cedars Ranch in Wimberley, Texas, which it will rebrand to Eddie Bauer Adventure Club – Texas Hill Country, the first “Outpost” in the Eddie Bauer Adventure Club portfolio. The 20-acre property sits among mature live oaks in the heart of Texas Hill Country, less than an hour outside Austin. Reservations for vacation club owners and guests will open in early 202...
E-Power's Mid-Sulfur Coke Anode Route Achieves 3.2% Higher Specific Capacity Than Conventional Low-Sulfur Coke
DOVER, USA, Oct. 23, 2026 (GLOBE NEWSWIRE) -- E-Power Inc. (“E-Power,” the “Company,” “we” or “our”) (NASDAQ: EPOW), a provider of advanced battery materials and AI Data Center (AIDC) microgrid solutions, today disclosed technical details of the mid-sulfur petroleum coke raw-material route used by its joint venture, Sunrise (Guizhou) New Energy Materials Co., Ltd. (“Sunrise Guizhou”), in its graphite anode materials for energy storage systems (“ESS”)...
Global Hemp Group Appoints Mickey Goldstein as Chief Financial Officer, Appoints Davidson & Company as Auditor
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to announce the appointment of Mickey Goldstein, CPA, CA, as Chief Financial Officer, effective immediately. Ms. Goldstein succeeds Christopher Cherry...
Blue Ribbon Income Fund Announces Monthly Distributions
Toronto, Ontario--(Newsfile Corp. - October 23, 2026) - Blue Ribbon Income Fund (TSX: RBN.UN) (the "Fund") announces distributions in the amount of $0.04 per unit per month for record dates from October to December 2026.
JBS to Host Third Quarter 2026 Earnings Call on November 10, 2026
AMSTELVEEN, Netherlands--(BUSINESS WIRE)--JBS N.V. (NYSE: JBS; B3: JBSS32) announced today that it will release its third quarter 2026 financial results after the U.S. market closes on Monday, November 9, 2026. The company's executives will review the results on a conference call and webcast on Tuesday, November 10, 2026, at 9:00 a.m. Eastern Time (11:00 a.m. Brasília Time). Prepared remarks regarding the company's financial and operational results will be followed by a question-and-answer sess...
GFG Closes Upsized Financing of $8.1 Million
GFG Secures Funding to Expand Aljo and Advance New Discoveries at Goldarm with Alamos Gold Maintaining 10.8% Interest NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION TO THE UNITED STATES. SASKATOON, Saskatchewan, Oct. 23, 2026 (GLOBE NEWSWIRE) -- GFG Resources Inc. (TSXV: GFG | OTCQB: GFGSF) (“GFG” or the “Company”) is pleased to announce that it has closed its previously announced best efforts private placement financing for aggregate gross proceeds of C$8.1 million (the “Offering”)...
AI OKTO Corp. Declares Special Dividend of $3.50 Per Share
LIMASSOL, Cyprus, Oct. 23, 2026 (GLOBE NEWSWIRE) -- AI OKTO Corp. (NASDAQ: AIOK) (“AI OKTO”, or the “Company”), an international ship-owning company providing energy transportation services globally, announced today that the Company's board of directors has declared a one-time, special dividend of $3.50 per common share, consisting of either cash or the Company's common shares. The dividend is payable to the Company's shareholders of record at the close of business on November 2, 2026 and is expected to be paid on or about November 25, 2026 (the “Dividend Payment Date”). Given that the payment of the special dividend represents more than 25% of the current trading price of the Company's common shares, Nasdaq has advised the Company that its common shares will trade with “due bills”. More information on this process is included below...
S&P Global Ratings launches interactive North America data center dashboard
New dashboard offers dynamic view of rated data center universe across Project Finance, Corporates, and Structured Finance Asset Backed Securities Covers 32 digital infrastructure transactions totaling $105.3 billion in debt issuance Includes market overview, issuer tear sheets and comparatives, and state-level capacity insights NEW YORK, Oct. 23, 2026 /PRNewswire/ -- S&P Global Ratings, the world's leading provider of independent credit ratings, today launched a new interactive dashboard providing a dynamic view of its rated North American data center universe across Project Finance, and Corporates, and Structured Finance asset-backed securities (SF ABS). The dashboard brings together information across these three areas, providing an overview of the market, issuer tear sheets and comparatives, and insights into states where capacity is being leased...
DEADLINE NEXT WEEK: Berger Montague Advises Hyliion Holdings Corp. (HYLN) Investors to Contact the Firm Before October 27, 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - October 23, 2026) - Berger Montague PC, a leading national plaintiffs' law firm, announces a class action lawsuit against Hyliion Holdings Corp. (NYSE American: HYLN) ("Hyliion" or the "Company") on behalf of investors who purchased or acquired Hyliion securities during the period from May 12, 2026 through June 23, 2026 (the "Class Period"). The deadline to apply for lead plaintiff is October 27, 2026...
Oregon Bancorp Announces Quarterly Earnings
SALEM, Ore.--(BUSINESS WIRE)--Oregon Bancorp, Inc. (OTCBB: ORBN) (the “Company”), parent company of Willamette Valley Bank, reported net income of $746 thousand, or $0.30 per share, for the third quarter of 2026, compared to net income of $604 thousand, or $0.24 per share, for the second quarter of 2026. The Company generated a return on average assets of 0.6% and a return on average equity of 4.0% for the quarter. Third-quarter results included $212 thousand of trailing expenses associated wit...
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
Lassonde Industries Inc. Will Hold a Conference Call To Discuss Its Third Quarter 2026 Financial Results
ROUGEMONT, Quebec, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Lassonde Industries Inc. (TSX: LAS.A) ("Lassonde" or the "Corporation") is pleased to announce that it will host a conference call to discuss its financial results for the third quarter of 2026 on Friday, November 6, 2026. Mr. Vince Timpano, Chief Executive Officer, and Mr. Francis Trudeau, Chief Financial Officer, will host the call...
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled “Characterising the efficacy of multi-node PI3K/AKT/mTOR pathway inhibition with serabelisib and sapanisertib (PIKTOR) in combination with SERDs and a CDK4/6...
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These results demonstrated durable activity across a broad range of solid tumors, which the Company believes supports expanded development of MGC026 in front-line metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab...
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over 500 days despite recurrent, metastatic melanoma carrying the BRAF V600E mutation and prior progression on targeted combination therapy with dabrafenib and trametinib. -- Long-Term Tolerability: Overall, the safety profile of PAS-004 in the heavily pre-treated advanced cancer population appears favorable...
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
MILLBRAE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain...
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening with the Cologuard test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoring ABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain...
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone
KANZHUN LIMITED Announces Board Change
BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that Mr. Haiyang Yu (“Mr. Yu”) has tendered his resignation as a non-executive director of the Company due to his other business commitments, with effect from October 23, 2026...
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana's pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned...